Extended Data Table 3 Effect of pegozafermin on markers of liver health and inflammation

From: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial

  1. Data are based on the full analysis set. Nonparametric methods were used for data that were highly skewed and did not meet normality assumptions.
Back to article page